New data demonstrated best-in-class potential for casdatifan, a hif-2a inhibitor, in patients with metastatic kidney cancer

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan, a hif-2a inhibitor with best-in-class potential, in an oral plenary session by dr. toni k. choueiri, dana-farber cancer institute, at the 2025 american society of clinical oncology (asco) genitourinary (gu) cancers symposium. “the newest d.
RCUS Ratings Summary
RCUS Quant Ranking